Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration
H. Kuss, N. Hoefgen, S. Johanssen, T. Kronbach and C. Rundfeldt
Journal of Pharmacology and Experimental Therapeutics October 2003, 307 (1) 373-385; DOI: https://doi.org/10.1124/jpet.103.053942
H. Kuss
N. Hoefgen
S. Johanssen
T. Kronbach
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 307, Issue 1
1 Oct 2003
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration
H. Kuss, N. Hoefgen, S. Johanssen, T. Kronbach and C. Rundfeldt
Journal of Pharmacology and Experimental Therapeutics October 1, 2003, 307 (1) 373-385; DOI: https://doi.org/10.1124/jpet.103.053942
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration
H. Kuss, N. Hoefgen, S. Johanssen, T. Kronbach and C. Rundfeldt
Journal of Pharmacology and Experimental Therapeutics October 1, 2003, 307 (1) 373-385; DOI: https://doi.org/10.1124/jpet.103.053942
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement